J Buvat's research while affiliated with University of Lille Nord de France and other places

... Можливо, стан гіпотиреозу сприяв більш ранньому прояву андрогенного дефіциту в схильних до нього чоловіків. Однак середній вік пацієнтів, які взяли участь у нашому дослідженні, становив 42-43 роки, а стан андропаузи, на думку спеціалістів у галузі вивчення андрогенного дефіциту, відзначається у чоловіків із середнім віком 60 років [14]. ...

... Randomized trials have failed to provide strong data supporting the efficacy of rehabilitation treatments with either oral drugs or intracavernous injections in increasing the probability of spontaneous EF recovery after RP. Notwithstanding, all trials have demonstrated that erectile aids lead to better postoperative EF status when using drugs compared to either placebo or no treatment [57]. However, our review showed that rehabilitation protocols and the use of erectile aids by patients after RS-RARP are scantly reported, providing room for improvement of EF outcomes. ...

... Although the development of nerve-sparing techniques has contributed to reducing the severity of some sideeffects, many men still suffer from long lasting implications due to their disease. Furthermore, rehabilitation processes following prostate cancer are influenced by the size and severity of the prostate tumour, the treatment techniques used, and age (Salonia et al. 2017). ...

... According to all the available guidelines released by several dedicated societies [5][6][7][8][9][10][11], TD should be treated only when specific symptoms are present. The main symptoms potentially associated with TD are rather nonspecific and vague and include sexual dysfunction, infertility, fatigue, sadness, poor concentration and memory, hot flashing, and decreased vigorous activity [12]. ...

... The enzyme, phosphodiesterase 5 (PDE-5), breaks down cGMP and causes an erection to subside [8]. Standard medications for improving penile erection work by inhibiting PDE-5, to maintain a high level of cGMP [9]. However, these medications can lead to resistance in some patients, increase the cost of care, and have side effects, such as headache, dizziness, indigestion, heartburn, flushing, and vasodilation [10,11]. ...

... Figure 2 shows the percentage of patients with clinically significant changes in IIEF EF [Figure Figure 2(b)] in subgroups with different medical history. Clinically significant improvements were seen in all three ED subcategories with 50%, 40%, and 22% of patients, respectively, with mild, moderate, and severe ED showing a clinically relevant change in the IIEF EF score [Buvat et al. 2012]. In patients who failed to respond to sildenafil and in those who previously used sildenafil, a consistent overall improvement in EF was observed, regardless of ED severity [Mulhall et al. 2013b]. ...

... La percepción del control sobre la eya-culación y la angustia personal relacionada con la EP mejoró significativamente con las dosis de 30 mg y 60 mg de dapoxetina frente a placebo en las semanas 12 y 24 (p<0,001 en ambas). El 57,7% y el 72,4% de los hombres de los grupos de tratamiento con 30 y 60 mg de dapoxetina respectivamente, valoraron su EP como un poco mejor, mejor o mucho mejor al final del tratamiento, en comparación con el 32,0% del grupo placebo 143 . Los resultados del estudio de la región Asia-Pacífico también mostraron mejoras significativas con dapoxetina en comparación con placebo para todas las medidas de PRO, incluidos el PEP y el CGIC. ...

... In addition, sociocultural standards dictate the meaning/interpretation of body morphology, and as such may not only impart independent effects on sexual functioning by creating expectations and stereotypes, but which may further exacerbate negative psychological fallout from the condition [37,39]. As such, the study of the association between obesity and impaired sexual functioning calls for an interdisciplinary and multivariate approach that explores various pathways 1 Based on information contained throughout [40] 2 Because various medications have the potential to negatively affect any of the phases of sexual response except pain, they are not included in the lists of associated etiological and risk factors not only in isolation but also as covariates in the analyses of concomitant pathways. Furthermore, understanding the nature of sexual response and dysfunction as noted in the previous section is important to the study of the relationship between obesity and sexual function for several reasons. ...

... LSmean scores increased by 7.1 points from baseline to 4-6 months (T3) after initiation of tadalafil OaD, exceeding the minimally clinically important difference (MCID) of four points (24), and were consistent with the 9.4-point increase observed with tadalafil OaD in the previous RCT (23). Overall, 86% of patients reported improvements in their ability to engage in sexual activity, consistent with 84% observed with tadalafil OaD in the RCT (25). ...

... Patient-reported outcome (PRO) measures included the Premature Ejaculation Profile (PEP) and clinical global impression of change (CGI;Table 1) [6,7]. Men and their partners completed the male and female versions of the PEP, respectively (partner results reported elsewhere [8]), and the CGI at baseline and at week 4, week 8, week 12, week 16, week 20, and week 24. A composite PRO definition of clinical benefit was applied based on the percentage of subjects achieving an increase of greater than or equal to two categories in control and a decrease of greater than or equal to one category in distress at week 12 and week 24. ...